Hundreds of billions of grass-roots market, Novarma, AstraZenecom and other multinational pharmaceutical companies to accelerate the beach layout

In recent years, with the power of national policies, medical resources are sinking to the grass-roots counties.
china's primary health care market share has exceeded 130 billion yuan.
With the promotion of the collection policy and the graded diagnosis and treatment policy, the level of primary diagnosis and treatment has been continuously improved, the ability of the grass-roots people to pay after the decline of drugs has also been improved, and the potential of the primary county medical market is becoming increasingly prominent, becoming an entry point for pharmaceutical companies, especially multinational pharmaceutical enterprises, to expand the market.
September 4, pharmaceutical giant Novarma announced at the 2020 China County Health Conference in Suzhou that it has reached a strategic cooperation with the Association of County Hospital Deans of China, and that the two sides will carry out in-depth and long-term cooperation in the fields of hypertension, blood sugar, lipids, heart failure, ophthalmology, immunocortology, central nervous system and transplantation to help build a national hierarchical diagnosis and treatment and localized disease management system to meet the needs of primary patients.
it is understood that the China County Hospital Deans Alliance was jointly initiated by the National Cardiovascular and Cerebrovascular Disease Alliance, the China Cardiovascular Health Alliance, the China-Japan Friendship Hospital, the Shanghai Medical and Health Development Foundation and a number of academicians.
Aims to meet the medical needs of primary-level patients by upgrading the comprehensive clinical skills of county medical institutions, and to achieve the strategic goal of national medical reform of "big sick counties".
county team was established in 2017-2018, in recent years, the rapid development of cardiovascular, immune, respiratory, central nervous and other product lines to achieve business sinking.
In accordance with Novart's cooperation opportunities, in the first phase of cooperation, the two sides will focus on professional discipline capacity-building and cardiovascular disease screening and management system construction, to help cardiovascular disease diagnosis and treatment in the county area of sustainable development, to meet the health needs of the county people.
unique, AstraZeneta announced in April that it had decided to set up a county cancer team, which would be broken down into lung cancer and non-lung cancer teams.
in the face of the vast number of primary cancer patients demand for innovative drugs, AstraZenecom plans to increase investment, so that the average county has a full-time tumor representative coverage, the county oncology team recruited a total of hundreds of people.
the follow-up team is also responsible for the entire county health system platform construction and provide innovative solutions to help build a healthy county system, so that "big illness out of the county" become a reality.
as early as 2015, AstraZeneta has set up a county team, the current number has reached about 4,500 people.
2019, AstraZenecom has also launched several rounds of recruitment for the county market, which covers many provinces and counties across the country.
early in the grass-roots layout also surprised AstraZeneta.
first half of 2020, AstraZene half-year revenue in China reached $2,659 million, up 14 per cent against the trend.
revenue growth was mainly due to the performance of the county market offset the decline in the performance of major cities.
addition to Novarma and AstraZeneta, Pfizer is also heavily supplementing pharmaceutical representatives in the county market.
Pfizer's Lipto (Atovastatin calcium tablets) and Lysin Hi (benzodiaxane chloride tablets) were out in the secondary harvest, put some pressure on Pfizer's performance.
but sales of both products were strong in the first half of the year, boosting Pfizer's second-quarter revenue by 17% year-on-year.
addition, Bayer (China), Merck (China), GSK (China) and other multinational pharmaceutical companies have repeatedly released the recruitment of pharmaceutical representatives, aiming at the grass-roots market to increase sales team building.
in general, the grass-roots market has become the focus of multinational pharmaceutical companies, the future as more enterprises to join the layout, for grass-roots doctors and patients, will be a great news.